Physician profile
Dannie Earl
NPI 1972575199
$10,442.16
in general payments reported to CMS, 2019-2025
35 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $2,022 · 2021: $371 · 2022: $918 · 2023: $1,459 · 2024: $1,727 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932 · Education: $4.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,931.68 |
| Education | $4.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,856.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,373.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,210.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $882.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $682.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.02 | 2019-2025 | Jardiance |
| Abbvie INC. | $613.55 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $409.05 | 2019-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $318.70 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $282.64 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.35 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $237.92 | 2023-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $222.47 | 2022 | |
| Exact Sciences Corporation | $217.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $151.49 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $142.40 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $136.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.47 | 2023-2025 | |
| Esperion Therapeutics, INC. | $121.75 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $101.97 | 2019-2023 | |
| Amarin Pharma, INC. | $81.36 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $58.94 | 2019-2021 | |
| Mylan Specialty L.P. | $36.14 | 2020 | |
| Abbott Laboratories | $36.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.55 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $23.66 | 2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $22.71 | 2025 | Voquezna |
| Ibsa Pharma INC. | $22.50 | 2023 | Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $22.45 | 2024 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $22.37 | 2024 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $21.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.82 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.94 | 2019 | |
| Allergan, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dannie Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.